GLP-1 receptor agonists, dual and triple agonists, oral GLP-1 formulations, amylin analogs, metabolic peptides, and prescription weight management agents targeting insulin sensitivity, appetite regulation, body composition, and metabolic longevity.
Browse all available metabolic & glp-1 therapies treatments and protocols.
Long-acting amylin analog; activates AMYR and CTR. In Phase III development. Being combined with semaglutide (CagriSema) in trials showing up to 22-25% weight loss at 32 weeks.
Once-weekly GLP-1 RA with IgG4-Fc fusion for extended half-life. FDA-approved for T2D and cardiovascular risk reduction. Brand name: Trulicity.
First FDA-approved GLP-1 RA. Derived from exendin-4. Available as twice-daily (Byetta) and weekly (Bydureon) formulations. Brand names: Byetta, Bydureon.
First-generation long-acting GLP-1 analog. FDA-approved for T2D (Victoza) and obesity (Saxenda 3mg). Daily injection. Brand names: Victoza, Saxenda.
Investigational triple agonist targeting GLP-1R, GIPR, and glucagon receptor. Phase II trials show up to 24% weight loss at 48 weeks — most powerful peptide weight loss to date.
Long-acting GLP-1 analog with C18 fatty acid chain for albumin binding (half-life ~1 week). FDA-approved for T2D (Ozempic), obesity (Wegovy), and oral form (Rybelsus). Shows cardiovascular and potential anti-Alzheimers benefits. Brand names: Ozempic, Wegovy, Rybelsus.
FDA-approved dual incretin mimetic (GLP-1 + GIP). Demonstrated superior weight loss (~20-22%) and glycemic control versus semaglutide in head-to-head trials. Brand names: Mounjaro, Zepbound.
Ask our AI research assistant for detailed information and research citations.